Caroline Mary

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 02, 2026

CLEC-1 Restrains Acute Inflammatory Response and Recruitment of Neutrophils following Tissue Injury.

CLEC-1 Restrains Acute Inflammatory Response and Recruitment of Neutrophils following Tissue Injury.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: July 17, 2023

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.

Journal: Blood

Published: May 08, 2023

ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression.

ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression.

Journal: Frontiers in immunology

Published: March 30, 2023

CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.

CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.

Journal: Science advances

Published: November 18, 2022

First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα.

First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 25, 2022

Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth.

Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth.

Journal: Cell death discovery

Published: July 20, 2021

SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation.

SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation.

Journal: Frontiers in immunology

Published: June 29, 2021

Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.

Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.

Journal: Science advances

Published: June 03, 2020

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.

Journal: The Journal of clinical investigation

Published: December 06, 2019

Interleukin-7 receptor blockade by an anti-CD127 monoclonal antibody in nonhuman primate kidney transplantation.

Interleukin-7 receptor blockade by an anti-CD127 monoclonal antibody in nonhuman primate kidney transplantation.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: March 12, 2019

SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells.

SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: November 22, 2018

Showing 1-12 of 29

Last Updated: 09/26/2026